Valuation: Cerus Corporation

Market Cap 627M 548M 506M 466M 879M 60.38B 899M 6.05B 2.38B 29.56B 2.36B 2.3B 102B P/E 2026 *
-93.9x
P/E 2027 * -940x
Enterprise Value 627M 548M 506M 466M 879M 60.38B 899M 6.05B 2.38B 29.56B 2.36B 2.3B 102B EV / Sales 2026 *
2.63x
EV / Sales 2027 * 2.41x
Free-Float
96.6%
Yield 2026 *
-
Yield 2027 * -
1 day-2.49%
1 week+0.32%
Current month+7.19%
1 month+21.79%
3 months+50.48%
6 months+20.38%
Current year+51.94%
1 week 2.92
Extreme 2.92
3.29
1 month 2.52
Extreme 2.52
3.47
Current year 1.62
Extreme 1.62
3.47
1 year 1.15
Extreme 1.15
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Director/Board Member 67 2019-03-03
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
6/30/26 Free

General Counsel

-79,329 0.0396%
6/30/26 Free

Chief Financial Officer

-97,276 0.0485%
Change 5-day change 1-year change 3-year change Capi.($)
-2.49%+0.32%+128.47%+23.23% 627M
-3.42%-3.01%-17.75%+7.12% 123B
-1.03%+0.96%+2.81%-2.62% 13.04B
+0.93%+2.69%+58.41%+100.45% 9.21B
+3.09%+12.41%-42.97%-67.87% 4.47B
-6.27%-0.13%+7.14%+44.15% 2.7B
-6.41%-7.36%-22.74%-31.80% 1.62B
-4.80%-0.43%-12.07%-21.60% 1.6B
-3.56%+5.13%-12.28%-58.35% 1.56B
Average -2.66%+2.05%+9.89%-0.81% 17.49B
Weighted average by Cap. -2.87%-1.65%-11.24%+9.00%

Financials

2026 *2027 *
Net sales 238M 208M 192M 177M 334M 22.93B 341M 2.3B 902M 11.22B 894M 875M 38.66B 260M 227M 210M 193M 364M 25.02B 372M 2.51B 984M 12.25B 976M 954M 42.18B
Net income -6.24M -5.45M -5.03M -4.64M -8.75M -601M -8.94M -60.16M -23.63M -294M -23.42M -22.91M -1.01B -479K -419K -387K -356K -672K -46.15M -687K -4.62M -1.82M -22.59M -1.8M -1.76M -77.82M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-07-17 $3.130 -2.49% 2,428,479
26-07-16 $3.210 +0.94% 1,852,870
26-07-15 $3.180 +3.58% 1,083,631
26-07-14 $3.070 -0.65% 1,922,363
26-07-13 $3.090 -0.96% 1,192,917
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.130USD
Average target price
4.667USD
Spread / Average Target
+49.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock